title: [Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer].
abstract: We present two cases of liver metastases from breast cancer treated by radiofrequency ablation (RFA) for elongation of life. Case 1: A 50-year-old woman was treated by left mastectomy (stage IIIa) in December 2002. In April 2004, she was treated with a combination therapy of weekly paclitaxel and trastuzumab for multiple liver metastases, left supraclavicular lymph node metastases, and multiple bone metastases. After 16 courses of weekly paclitaxel and trastuzumab, liver metastases decreased significantly in size. Because liver metastases recurred during a continuation of weekly paclitaxel and trastuzumab, we performed RFA and chemotherapy using a hepatic artery infusion of docetaxel for liver metastasis. The aggravation spread to the liver lesion and she died after 20 months from liver metastases. Case 2: A 65-year-old woman was treated by left mastectomy (stage IIA) in 1984, and the distant metastasis was not found through the course after an operation. She was noted with a liver function aberration in another hospital in March 2005. We scanned it, and it was diagnosed as multiple liver and bone metastases from breast cancer. Because she did not hope for an anticancer drug treatment for multiple liver metastases, we performed RFA in May 2005. After the second RFA was performed, she does not show any new lesion to the liver for 10 months.
authors.affiliation: Dept of Surgery, Sasaki Institute Kyoundo Hospital.
authors.forename: Takanobu
authors.initials: T
authors.lastname: Sato
authors.forename: Shinpei
authors.initials: S
authors.lastname: Sato
authors.forename: Keiji
authors.initials: K
authors.lastname: Kato
authors.forename: Hidefumi
authors.initials: H
authors.lastname: Tsunozaki
authors.forename: Takeo
authors.initials: T
authors.lastname: Iwama
authors.forename: Kumiko
authors.initials: K
authors.lastname: Karasawa
authors.forename: Toshio
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology* / Q000601:surgery; D017115:Catheter Ablation; D000077143:Docetaxel; D017809:Fatal Outcome; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D008207:Lymphatic Metastasis; D008408:Mastectomy; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D043823:Taxoids; D000077143:Docetaxel; D000068878:Trastuzumab; D017239:Paclitaxel